Transplacentally transferred functional antibodies against Plasmodium falciparum decrease with age

Acta Tropica

Volumn 128, Issue 1, 2013, Pages 149-153

  Wilson, Patrick T ^a   Malhotra, Indu ^a   Mungai, Peter ^a,b   King, Christopher L ^a   Dent, Arlene E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Vector Borne Diseases   (Kenya)

Author keywords

Functional antibodies; Growth inhibition assay; Malaria; Plasmodium falciparum

Indexed keywords

PARASITE ANTIBODY; PLASMODIUM FALCIPARUM ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY; GROWTH; INHIBITION; MALARIA; PARASITE; PROTOZOAN;

AGE; ARTICLE; ASSAY; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION ASSAY; HUMAN; INFANT; MALARIA FALCIPARUM; NONHUMAN; PLACENTAL TRANSFER; PLASMODIUM FALCIPARUM; PREGNANT WOMAN; UMBILICAL CORD BLOOD; WILCOXON SIGNED RANKS TEST;

PLASMODIUM FALCIPARUM;

FUNCTIONAL ANTIBODIES; GROWTH INHIBITION ASSAY; MALARIA; PLASMODIUM FALCIPARUM;

ADULT; AGE FACTORS; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALARIA; PLASMODIUM FALCIPARUM; PREGNANCY; YOUNG ADULT;

EID: 84883742525     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.07.018     Document Type: Article

References (36)

1. Ahlborg N., Ling I.T., Holder A.A., Riley E.M. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). Infection and Immunity 2000, 68:2102-2109.
2. Beeson J.G., Brown G.V., Molyneux M.E., Mhango C., Dzinjalamala F., Rogerson S.J. Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties. Journal of Infectious Diseases 1999, 180:464-472.
3. Bei A.K., Desimone T.M., Badiane A.S., Ahouidi A.D., Dieye T., Ndiaye D., Sarr O., Ndir O., Mboup S., Duraisingh M.T. A flow cytometry-based assay for measuring invasion of red blood cells by Plasmodium falciparum. American Journal of Hematology 2010, 85:234-237.
4. Bolad A., Nebie I., Cuzin-Ouattara N., Traore A., Esposito F., Berzins K. Antibody-mediated in vitro growth inhibition of field isolates of Plasmodium falciparum from asymptomatic children in Burkina Faso. American Journal of Tropical Medicine and Hygiene 2003, 68:728-733.
5. Costa-Carvalho B.T., Vieria H.M., Dimantas R.B., Arslanian C., Naspitz C.K., Sole D., Carneiro-Sampaio M.M. Transfer of IgG subclasses across placenta in term and preterm newborns. Brazilian Journal of Medical and Biological Research 1996, 29:201-204.
6. Crompton P.D., Miura K., Traore B., Kayentao K., Ongoiba A., Weiss G., Doumbo S., Doumtabe D., Kone Y., Huang C.Y., Doumbo O.K., Miller L.H., Long C.A., Pierce S.K. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infection and Immunity 2010, 78:737-745.
7. Darko C.A., Angov E., Collins W.E., Bergmann-Leitner E.S., Girouard A.S., Hitt S.L., McBride J.S., Diggs C.L., Holder A.A., Long C.A., Barnwell J.W., Lyon J.A. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infection and Immunity 2005, 73:287-297.
8. Dent A., Malhotra I., Mungai P., Muchiri E., Crabb B.S., Kazura J.W., King C.L. Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. Journal of Immunology 2006, 177:7139-7145.
9. Dent A.E., Bergmann-Leitner E.S., Wilson D.W., Tisch D.J., Kimmel R., Vulule J., Sumba P.O., Beeson J.G., Angov E., Moormann A.M., Kazura J.W. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS ONE 2008, 3:e3557.
10. Dicko A., Diemert D.J., Sagara I., Sogoba M., Niambele M.B., Assadou M.H., Guindo O., Kamate B., Baby M., Sissoko M., Malkin E.M., Fay M.P., Thera M.A., Miura K., Dolo A., Diallo D.A., Mullen G.E., Long C.A., Saul A., Doumbo O., Miller L.H. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE 2007, 2:e1045.
11. Diggs C., Joseph K., Flemmings B., Snodgrass R., Hines F. Protein synthesis in vitro by cryopreserved Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene 1975, 24:760-763.
12. Dodoo D., Aikins A., Kusi K.A., Lamptey H., Remarque E., Milligan P., Bosomprah S., Chilengi R., Osei Y.D., Akanmori B.D., Theisen M. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malaria Journal 2008, 7:142.
13. Duraisingh M.T., Maier A.G., Triglia T., Cowman A.F. Erythrocyte-binding antigen 175 mediates invasion in Plasmodium falciparum utilizing sialic acid-dependent and -independent pathways. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4796-4801.
14. Hadley T.J., Klotz F.W., Pasvol G., Haynes J.D., McGinniss M.H., Okubo Y., Miller L.H. Falciparum malaria parasites invade erythrocytes that lack glycophorin A and B (MkMk). Strain differences indicate receptor heterogeneity and two pathways for invasion. Journal of Clinical Investigation 1987, 80:1190-1193.
15. Izumiyama S., Omura M., Takasaki T., Ohmae H., Asahi H. Plasmodium falciparum: development and validation of a measure of intraerythrocytic growth using SYBR Green I in a flow cytometer. Experimental Parasitology 2009, 121:144-150.
16. Johnson J.D., Dennull R.A., Gerena L., Lopez-Sanchez M., Roncal N.E., Waters N.C. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Antimicrobial Agents and Chemotherapy 2007, 51:1926-1933.
17. Kasehagen L.J., Mueller I., McNamara D.T., Bockarie M.J., Kiniboro B., Rare L., Lorry K., Kastens W., Reeder J.C., Kazura J.W., Zimmerman P.A. Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. American Journal of Tropical Medicine and Hygiene 2006, 75:588-596.
18. Macdonald G. The analysis of malaria parasite rates in infants. Tropical Diseases Bulletin 1950, 47:915-938.
19. Malhotra I., Dent A., Mungai P., Wamachi A., Ouma J.H., Narum D.L., Muchiri E., Tisch D.J., King C.L. Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS Medicine 2009, 6:e1000116.
20. Marsh K., Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunology 2006, 28:51-60.
21. McCallum F.J., Persson K.E., Mugyenyi C.K., Fowkes F.J., Simpson J.A., Richards J.S., Williams T.N., Marsh K., Beeson J.G. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS ONE 2008, 3:e3571.
22. McGuinness D., Koram K., Bennett S., Wagner G., Nkrumah F., Riley E. Clinical case definitions for malaria: clinical malaria associated with very low parasite densities in African infants. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998, 92:527-531.
23. Miura K., Zhou H., Moretz S.E., Diouf A., Thera M.A., Dolo A., Doumbo O., Malkin E., Diemert D., Miller L.H., Mullen G.E., Long C.A. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. Journal of Immunology 2008, 181:8776-8783.
24. Mu J., Awadalla P., Duan J., McGee K.M., Keebler J., Seydel K., McVean G.A., Su X.Z. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nature Genetics 2007, 39:126-130.
25. Ord R.L., Rodriguez M., Yamasaki T., Takeo S., Tsuboi T., Lobo C.A. Targeting sialic acid dependent and independent pathways of invasion in Plasmodium falciparum. PLoS ONE 2012, 7:e30251.
26. Palmeira P., Quinello C., Silveira-Lessa A.L., Zago C.A., Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clinical and Developmental Immunology 2012, 2012:985646.
27. Perraut R., Marrama L., Diouf B., Sokhna C., Tall A., Nabeth P., Trape J.F., Longacre S., Mercereau-Puijalon O. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. Journal of Infectious Diseases 2005, 191:264-271.
28. Persson K.E., Lee C.T., Marsh K., Beeson J.G. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. Journal of Clinical Microbiology 2006, 44:1665-1673.
29. Rono J., Farnert A., Olsson D., Osier F., Rooth I., Persson K.E. Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria. Infection and Immunity 2012, 80:1900-1908.
30. Singh S., Kennedy M.C., Long C.A., Saul A.J., Miller L.H., Stowers A.W. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infection and Immunity 2003, 71:6766-6774.
31. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., Martin L.B., Saul A.J., Miller L.H., Long C.A. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infection and Immunity 2006, 74:4573-4580.
32. Sy N.E., Oberst R.B., Macalagay P.S., Fallarme V.D., Cruzada S.F., Laughlin L.W. In vitro growth inhibition of Plasmodium falciparum by sera from different regions of the Philippines. American Journal of Tropical Medicine and Hygiene 1990, 43:243-247.
33. Thera, Doumbo M.A., Coulibaly O.K., Diallo D., Sagara D.A., Dicko I., Diemert A., Heppner D.J., Stewart D.G., Angov V.A., Soisson E., Leach L., Tucker A., Lyke K., Plowe K.E., Mali C.V., Working Group F.M.P. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS Clinical Trials 2006, 1:e34.
34. Wahlin Flyg B., Perlmann H., Perlmann P., Esposito F., Berzins K. Wild isolates of Plasmodium falciparum malaria show decreased sensitivity to in vitro inhibition of parasite growth mediated by autologous host antibodies. Clinical & Experimental Immunology 1997, 107:321-327.
35. Withers M.R., McKinney D., Ogutu B.R., Waitumbi J.N., Milman J.B., Apollo O.J., Allen O.G., Tucker K., Soisson L.A., Diggs C., Leach A., Wittes J., Dubovsky F., Stewart V.A., Remich S.A., Cohen J., Ballou W.R., Holland C.A., Lyon J.A., Angov E., Stoute J.A., Martin S.K., Heppner D.G.JJr, M.S.P.Malaria Vaccine Working Group Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clinical Trials 2006, 1:e32.
36. Zhou Z., Xiao L., Branch O.H., Kariuki S., Nahlen B.L., Lal A.A. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. American Journal of Tropical Medicine and Hygiene 2002, 66:7-12.